{
    "clinical_study": {
        "@rank": "90930", 
        "brief_summary": {
            "textblock": "RATIONALE: Vaccines made from papilloma virus cells may make the body build an immune\n      response to and kill papilloma cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of papilloma virus vaccine in treating\n      young patients with recurrent papilloma of the larynx."
        }, 
        "brief_title": "Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx", 
        "condition": "Precancerous Condition", 
        "condition_browse": {
            "mesh_term": [
                "Papilloma", 
                "Precancerous Conditions"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Determine the immune response in patients with juvenile papilloma of the\n      larynx treated with autogenous vaccine derived from each patient's own tumor.\n\n      OUTLINE: Patients receive autogenous papilloma vaccine intradermally and subcutaneously\n      weekly for 20 weeks.\n\n      PROJECTED ACCRUAL: Not specified"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Diagnosis of severe recurrent juvenile papilloma of the larynx\n        requiring surgery at least 4 times per year Condition must have existed for more than 1\n        year\n\n        PATIENT CHARACTERISTICS: Age: 1 and over Performance status: Not specified Life\n        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not\n        specified\n\n        PRIOR CONCURRENT THERAPY: See Disease Characteristics"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "1 Year"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002454", 
            "org_study_id": "CDR0000071657", 
            "secondary_id": [
                "NJ-LAR-1", 
                "NJ-M-41-1976"
            ]
        }, 
        "intervention": {
            "intervention_name": "autologous tumor cell vaccine", 
            "intervention_type": "Biological"
        }, 
        "keyword": "lung papilloma", 
        "lastchanged_date": "July 23, 2011", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/NJ-LAR-1"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Newark", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07103-2714"
                }, 
                "name": "New Jersey Medical School"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx", 
        "overall_official": {
            "affiliation": "Rutgers, The State University of New Jersey", 
            "last_name": "James M. Oleske, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002454"
        }, 
        "results_reference": {
            "PMID": "4326367", 
            "citation": "Oleske JM, Kushnick T. Juvenile papilloma of the larynx. Am J Dis Child. 1971 May;121(5):417-9. No abstract available."
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Medicine and Dentistry of New Jersey", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 1971", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2002"
    }, 
    "geocoordinates": {
        "New Jersey Medical School": "40.736 -74.172"
    }
}